PRESS RELEASE - REGULATED INFORMATION
Thursday, 31 August 2017, 07:01 CEST
BIOCARTIS ANNOUNCES 2017 HALF-YEAR RESULTS ON 7 SEPTEMBER 2017
Mechelen, Belgium, 31 August 2017 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it will report its half-year 2017 results and outlook for the remainder of the year on 7 September 2017 at 07:00h CEST.
The Biocartis management team will host a conference call with live webcast presentation on the day of the results announcement, 7 September 2017, at 14:00h CEST / 13:00h BST (UK) / 08:00h EDT (US). The live webcast can be accessed here. If you would like to participate in the questions and answers session, please dial in 5-10 minutes prior to the start time using the numbers below and confirmation code 4254599.
Participants, New York, US: +1 212 444 0896
Participants, London, UK: +44 (0)20 3427 1902
Participants, Paris, France: +33 (0)1 76 77 22 24
Participants, Amsterdam, Netherlands: +31 (0)20 716 8256
Participants, Brussels, Belgium: +32 (0)2 404 0662
The conference call and webcast will be conducted in English. A replay of the webcast will be available on the Biocartis investors website shortly after.
--- END ---
Manager Corporate Communications & Investor Relations Biocartis
tel +32 15 631 729
mobile +32 471 53 60 64
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers ten oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.
The Biocartis trademark and logo are trademarks of Biocartis and are used and registered in Europe. Idylla(TM) is a registered trademark in the United States and other countries. The Idylla(TM) trademark and logo are trademarks of and used by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.
This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release. You should not place undue reliance on forward-looking statements.